Hainan Longevity
Guides & research · Is stem cell therapy legal in China?

Is stem cell therapy legal in China? The 2026 rules, explained

Yes — inside a licensed hospital, for a licensed disease indication, under a regulatory frame that was rewritten in 2026. No — as an “anti-ageing injection” anywhere on the mainland. Here is the whole picture, including what changed on 1 May 2026 and how to tell a lawful program from a clinic advertisement.

The short answer

Stem cell therapy in China is legal in three narrow situations and illegal in most of the ways it is marketed. It is lawful as clinical research at a filed tertiary hospital, where participants may not be charged. It is lawful as licensed clinical treatment for a specific disease indication that the health authority has approved for fee-charging use — which, on the mainland, has so far happened almost entirely inside the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. And it is lawful as an approved drug: as of 2026 China has licensed exactly one stem cell medicine, a mesenchymal product for a complication of bone-marrow transplantation, approved in early 2025.

Everything else — the stem cell “youth injection” sold by a beauty salon, a wellness club, a private clinic without a filing, or a cell company that says it “partners with a top hospital” — sits outside the law, and since May 2026 outside it with penalties of five to twenty times the illegal proceeds. In mid-July 2026 the National Health Commission said this in as many words at a press briefing: beauty salons, wellness centres and cell-technology companies may not perform stem cell diagnosis or treatment of any kind, and experimental products may not be used clinically or sold to patients.

How the law got here — a timeline

2009. Stem cell and immune-cell treatments were classed as a “category-three medical technology”, which meant hospitals could offer and charge for them with provincial approval. Uptake was fast and oversight was thin.
2013. On 28 February the State Council approved the Boao Lecheng pilot zone in Hainan, with nine special policies later summarised as four “licences” — for medicine, research, operation and international exchange. The zone’s purpose was to let approved-abroad drugs, devices and frontier techniques be used lawfully in real hospitals before nationwide approval.
2015. The national stem cell clinical-research rules arrived: stem cell work was confined to research at filed tertiary hospitals, participants could not be charged, and advertising was prohibited. The category-three route was closed. For the next decade, “legal stem cell therapy on the mainland” meant a free research protocol or nothing.
2016. The death of a young patient after an unproven immune-cell treatment sold through a hospital contract prompted a nationwide halt to fee-charging cell therapy. Cell treatment moved firmly into the research-or-drug-approval lane.
December 2024 – February 2025. Hainan passed a regulation promoting new biomedical technologies inside the pilot zone, effective 1 February 2025. It created the first lawful route on the mainland for a hospital to translate a completed cell-therapy study into a fee-charging clinical service — for a named disease, at a filed price, with mandatory outcome reporting into the zone’s real-world data program.
March 2025 onward. The zone published its first batch of approved cell and gene technologies. By spring 2026 there were five batches: more than twenty cell and gene technologies (29 new biomedical technologies in all), for indications including knee osteoarthritis, liver cirrhosis, type-2 diabetes, chronic obstructive pulmonary disease and ischaemic heart disease, plus autologous immune-cell programs for cancer patients after surgery.
October 2025 – May 2026. The State Council issued Order No. 818, the Regulations on the Clinical Research and Clinical Translation of New Biomedical Technologies, in force from 1 May 2026, with the health commission’s approval procedures following on 30 April. It is the first national statute to govern cell therapy, gene therapy, tissue and organ techniques, microbiome transplants and brain–computer interfaces as a single class.

What Order 818 actually says

Order 818 is widely described in China as the strictest regulation the cell industry has ever faced, and also as the first to give it a lawful path to being paid. Both are true. Its core provisions are these.

Research. Clinical research on a new biomedical technology may only be run by top-tier (tertiary-A) hospitals meeting set conditions, must be filed with the National Health Commission, and must not charge participants any fee connected with the study. Multi-centre confirmation of safety and efficacy is expected before any translation.

Translation. When research is complete, the hospital may apply to the National Health Commission for approval to translate the technology into clinical use and to charge for it under published rules. The commission’s April 2026 procedures narrow the scope deliberately: the route is meant for highly individualised techniques that cannot become standardised drugs, and for rare or unmet conditions — not as a cheaper substitute for drug registration.

Enforcement. County-level and higher health authorities inspect both research and translated use. Violations carry fines of five to twenty times the illegal gain, plus personal penalties and licence revocation for those responsible. Providers that are not medical institutions have no lawful role at all.

The immediate effect on the ground, reported across Chinese business press in spring 2026, was the wind-down of the grey “anti-ageing stem cell” trade and of hospital-run “compassionate” cell programs that had charged culture fees, alongside a rush by tertiary hospitals to build GMP cell-manufacturing suites and file lawful projects.

What is — and is not — a licensed indication

This is the distinction that matters most to anyone considering treatment. Under the zone’s rules and now under Order 818, a cell or gene technology is licensed for a disease, named in the approval, with filed inclusion and exclusion criteria. At Boao Lecheng the approved list is built around conditions such as knee osteoarthritis, liver cirrhosis, type-2 diabetes, COPD and ischaemic heart failure for stem-cell programs, and post-surgical recurrence prevention across several solid tumours for autologous NK cell therapy. Each program is delivered as clinical-stage treatment in a tertiary hospital, with every course reported into the national real-world data program as a condition of the licence. The licensed programs, and what they cost →

The zone publishes those approvals rather than leaving them to be inferred, in numbered batches naming the indication and the hospital licensed to deliver it. Stem cell therapy in China: which conditions are approved, and where → sets out all twenty technologies and the six newest in full.

What is not a licensed indication anywhere on the mainland: longevity, rejuvenation, “whole-body anti-ageing”, hair and skin regeneration for the healthy, or “immune optimisation” without a diagnosis. Mainland regulation confines cell therapy to disease treatment, and the zone’s hospitals hold their approvals on that basis. Longevity is a real goal, and the retreat pursues it — through diagnostics, the six-axis wellness system and a year of follow-up — but not with a syringe of cells. If someone offers you the reverse, the offer itself tells you where they stand with the law.

How to tell a licensed program from a clinic advertisement

Six questions separate the two, and a lawful program answers all six without hesitation.

1. Who is the treating institution? A named tertiary hospital, inside the pilot zone, with the technology on a published approval batch. Not a clinic, a “centre”, a cell company, or a hotel.
2. What is the indication? A diagnosed disease that appears in the hospital’s filing, with written inclusion and exclusion criteria — which means some patients are declined. A program that accepts everyone has no criteria.
3. Where are the cells made? In a licensed GMP facility, with each batch released only after viability, identity, sterility and endotoxin testing. Ask to see the release certificate; a lawful program has one. How cell products are made and released →
4. Is the outcome reported? In the zone, yes — into the national real-world data program, mandatorily. That reporting is what makes the therapy “clinical-stage” rather than merely experimental.
5. What is promised? Nothing. Chinese law forbids advertising a stem cell treatment and forbids promising a cure. A lawful program describes what the therapy is meant to do and what it cannot do; an unlawful one describes a transformation.
6. Is the fee for a licensed clinical service? A translated technology has a filed fee for the treatment itself. A research study may charge nothing. A “cell culture fee” paid to a company rather than a hospital is the signature of the grey market Order 818 was written to close.

Hospital grade, accreditation and what each one actually proves

Question 1 above turns on a word most international patients meet for the first time in China, so it is worth unpacking. China grades its hospitals on three tiers, each subdivided A, B and C; the top rung is 三级甲等 — tertiary grade-A, written in English as Class 3A. It is an accreditation awarded by the health authority on departmental range, bed count, staffing, teaching and research capacity, and it is reviewed periodically rather than held for life.

What makes the hospital grade legally load-bearing rather than a badge: Order 818 restricts clinical research on a new biomedical technology to tertiary-A hospitals meeting set conditions, and the translation route runs from that research. A standalone clinic, a “longevity centre” or a cell company cannot hold the grade at all — which is why the first question separates a lawful program from an advertisement in a single word.

JCI accreditation is a different instrument. JCI is a voluntary, US-originated international standard that audits patient safety and clinical process; a minority of Chinese hospitals hold it, and it is genuinely useful for an international patient reading unfamiliar paperwork. But it is not a Chinese licence. A hospital can be JCI-accredited and hold no cell-therapy approval, or hold several approvals and no JCI. Neither substitutes for the other.
Two registers, two signatures. The National Health Commission files the research and approves the translation of a technology into paid clinical use. The NMPA licenses drugs — the single approved stem cell medicine went through NMPA; the zone’s project list did not. Conflating the two registers is how “approved in China” gets overclaimed in English-language marketing.
Ethics committee and informed consent. Filed research and translated clinical use both require review by the hospital’s ethics committee and written informed consent in a language you actually read. Ask for the consent document before you book a flight rather than on the morning of treatment; a licensed program can send it, and a reluctance to is itself an answer.

And there is a list to check against. The pilot zone publishes each approved cell and gene technology in a numbered batch with its landing institution named: across five batches to spring 2026, roughly twenty projects, with 784 recorded patient courses in total as reported at the zone’s March 2026 stem cell conference. The fifth batch’s six projects were assigned to Shulan (Boao) Hospital, Ciming Boao International Hospital, West China Lecheng Hospital of Sichuan University, Boao Super Hospital and Ruijin Hospital Hainan, covering decompensated liver cirrhosis, type-2 diabetes and several solid-tumour indications. You do not have to take anyone’s word for the pairing — ask which published project and which named hospital, and check that the two go together. The hospitals of the pilot zone →

How the national rules and the zone fit together

An honest guide has to say that this is still settling. Hainan’s 2025 regulation was the pioneer; Order 818 is the national law that followed it. Where they agree — tertiary hospitals only, disease indications only, filed criteria, outcome reporting, no fees for research — the zone’s programs already comply, and the zone’s five batches are the mainland’s working precedent for translation. Where a local rule conflicts with the national one, the national one governs; the health commission has said that classification details for “same-mechanism” technologies will be issued separately. We track this closely because our guests depend on it, and this page is updated as the frame moves. What does not change is the direction: tighter, more clinical, more transparent — which is the direction any patient should want.

What this means for an international patient

The same law applies to you as to a Chinese citizen, which is the point. A foreign passport buys no exemption and needs none: if your condition is a licensed indication and the treating hospital’s panel accepts you against its filed criteria, treatment is lawful, documented and reported. If it is not, the hospital will decline — and we consider that a feature of the system rather than a disappointment. Candidacy is decided from your records and from the retreat’s day-two assessment, so the assessment always comes first — and a diagnosis or prescription from your own physician at home is a valid starting point: bring it, and the panel reviews it against the same filed criteria. Stem cell programs are paused for longevity-only use; for a diagnosed condition they run as before, and the partner hospitals also offer a range of non-cell longevity programs that carry no such restriction. What happens on a longevity retreat →

If you are comparing this against a programme in another country, the test that travels is not the country but the legal route: a clinical trial, a licensed pathway with a filed indication, or physician discretion under general medical-practice licensing. Order 818 is frequently summarised abroad as a ban, when what it did was define the lawful route and close the unlicensed one. How Vietnam, Japan, Thailand and China compare, and what to ask any provider →

Two practical notes. Bring your home doctor into the conversation early; a licensed program is an adjunct to the plan your own specialists have set, never a replacement for it. And keep your paperwork: the treatment record, the batch release certificate and the follow-up schedule are yours, written in English, and they are what a physician at home will want to see.

Frequently asked

Is stem cell therapy legal in China? Yes, in three forms: as filed clinical research at a tertiary hospital (free to participants), as a licensed fee-charging clinical treatment for an approved disease indication — so far concentrated in Hainan’s Boao Lecheng pilot zone — and as one approved stem cell drug. Selling stem cell treatment outside a licensed medical institution, or for an unapproved use such as anti-ageing, is illegal.
What is China’s Order 818? State Council Order No. 818 is the Regulations on the Clinical Research and Clinical Translation of New Biomedical Technologies, issued in October 2025 and in force from 1 May 2026. It restricts research to filed tertiary hospitals, bans charging research participants, creates an approval route for translating completed research into paid clinical use, and sets penalties of five to twenty times illegal gains.
Can I get stem cell therapy for anti-ageing in China? No. Anti-ageing, rejuvenation and longevity are not licensed indications anywhere on the mainland; the National Health Commission has specifically warned against “anti-ageing injection” marketing. Licensed cell therapy is for diagnosed disease only. Longevity programs at the retreat are built on diagnostics and wellness, not on cell infusions.
Why is stem cell therapy legal in Boao Lecheng but not elsewhere in China? The zone was chartered by the State Council in 2013 to deliver frontier medicine lawfully under supervision before nationwide approval, and Hainan’s February 2025 regulation gave its hospitals the mainland’s first route to translate completed cell-therapy research into licensed, fee-charging treatment for named diseases. The national Order 818 of May 2026 now provides a similar route nationwide, with the zone’s five approval batches as the working precedent.
Is stem cell therapy in China safe? Legal and safe are different questions. Licensed programs run in tertiary hospitals with GMP-manufactured, release-tested cells and mandatory outcome reporting, which is the strongest safety frame available to a patient outside a formal trial; but the therapies are clinical-stage and carry genuine uncertainty. See our safety and regulation guide.
How do I know a Chinese stem cell program is licensed? The treating institution is a tertiary hospital inside the pilot zone; the indication appears on a published approval batch; there are written inclusion and exclusion criteria; the cells come with a GMP batch release certificate; outcomes are reported into the real-world data program; and nothing is promised. A program that fails any one of these is not what it claims.
Is a Chinese hospital’s Class 3A grade the same as JCI accreditation? No — they are different instruments and only one of them is a licence. Class 3A (三级甲等, tertiary grade-A) is the top rung of China’s own three-tier hospital grading system, awarded by the health authority on departmental range, staffing, teaching and research capacity, and reviewed periodically. Order 818 restricts clinical research on a new biomedical technology to tertiary-A hospitals, so the grade is a legal precondition of a cell-therapy licence. JCI accreditation is a voluntary international patient-safety standard held by a minority of Chinese hospitals; it is reassuring on process and says nothing at all about whether a particular cell technology is approved.
How do I check which hospital is licensed for a cell therapy in Hainan? Ask for the published project and the named institution, then check that the two match. The pilot zone publishes each approved cell and gene technology in a numbered batch with its landing hospital named — across five batches to spring 2026, roughly twenty projects, with 784 recorded patient courses in total as reported at the zone’s March 2026 stem cell conference. The fifth batch’s six projects were assigned to Shulan (Boao) Hospital, Ciming Boao International Hospital, West China Lecheng Hospital of Sichuan University, Boao Super Hospital and Ruijin Hospital Hainan, covering decompensated liver cirrhosis, type-2 diabetes and several solid-tumour indications. A program that cannot name its batch project and its treating institution is not on that list.
Write to us →Tell us where you’re starting from — a care manager replies within one working day.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.